Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/JPRN-jRCT2080221294
JPRN-jRCT2080221294UnknownPhase 2

A phase 2 dose exploratory study of K-877

Kowa Co., Ltd.0 sites192 target enrollmentStarted: November 2, 2010Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 2
Enrollment
192
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 20age old to <= 75age old (—)
Sex
All

Inclusion Criteria

  • •Dyslipidemia with high TG and low HDL-C

Exclusion Criteria

  • •The subject who need to be taken any other anti lipidemic agent

Investigators

Similar Trials

Unknown
Phase 1
Clinical pharmacology study of K-877Dyslipidemia
JPRN-jRCT2080222359Kowa Co., Ltd.32
Unknown
Phase 1
clinical pharmacology study of K-877Dyslipidemia
JPRN-jRCT2080222360Kowa Co., Ltd.24
Unknown
Phase 3
Dose-finding study of K-877 in combination with pitavastatiDyslipidemia
JPRN-jRCT2080221795Kowa Co., Ltd.168
Unknown
Phase 2
A dose finding study of KRN125Chemotherapy-induced neutropenia
JPRN-jRCT2080220922Kyowa Hakko Kirin Co., Ltd.
Unknown
Phase 1
Phase 1 study of KHK7580
JPRN-jRCT2080222486Kyowa Hakko Kirin Co., Ltd.8
A phase 2 dose exploratory study of K-877 | Clinical Trial